Reports Q4 revenue $18M vs. $19.5M last year. The company said, "Our performance in 2022 was focused on our core flagship haemoglobins business, where our main diabetes product line experienced 27% overall revenue growth and over 60% higher instrument placements versus 2021. As highlighted by the 43% growth in sales of high-margin diabetes consumables in Q4, 2022 versus Q4, 2021, the increased instrument placements position the Company for strong recurring revenues in contracted consumables sales over the next several years. We expect to expand on this strategy with the expected U.S. launch of our Premier Resolution Haemoglobin Variants instrument this year as we continue to work closely with the FDA to gain clearance of our 510(k) submission."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRIB:
- Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
- Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm
- Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
- Trinity Biotech enters increased loan facility to fund potential acquisitions
- Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions
